Sustaining HIV, hepatitis and STIs services amid declining health aid

WHO validates Brazil for eliminating mother-to-child transmission of HIV

WHO’s new guidance on maintaining opioid agonist maintenance treatment as an essential health service

Lenacapavir approved in Zambia and Zimbabwe in record time through WHO Collaborative Registration Procedure

New prevention tools and investment in services essential in the fight against AIDS

WHO launches new framework to tackle drug resistance to HIV, hepatitis B and C, and STIs

Maldives becomes the first country to achieve ‘triple elimination’ of mother-to-child transmission of HIV, syphilis and hepatitis B

WHO released updated guideline on HIV service delivery

WHO announces the development of guidelines on multiplex testing

Redefining the HIV response in Africa through local production of medicines and diagnostics

First-ever guidance for Triple Elimination of mother-to-child transmission of HIV, syphilis and hepatitis B

WHO recommends rapid treatment initiation for people living with HIV and mpox

Integrating HIV, viral hepatitis and sexually transmitted infections with primary health care: learning from countries

New WHO guidance on HIV disclosure for children and adolescents

WHO prequalifies the first triple diagnostic test for HIV, hepatitis B and syphilis, a milestone toward global disease elimination goals

WHO recommends injectable lenacapavir for HIV prevention

WHO-backed integrated testing model strengthens response to mpox, HIV, and syphilis

FDA approval of injectable lenacapavir marks progress for HIV prevention

Botswana advances to gold tier on the Path to Elimination of mother-to-child transmission of HIV

HIV, Hepatitis and Sexually Transmitted Infections agenda at the Seventy-eighth World Health Assembly

WHO and Medicines Patent Pool announce sublicensing agreement for rapid diagnostic test technology